16.65  -0.47 (-2.75%)		07-31 16:00
Open: 16.995 High: 17.59 Volume: 907,965		Pre. Close: 17.12 Low: 16.24 Market Cap: 1,295(M)

Short term
Mid term
Targets	6-month :	21.98	1-year :	23.93
Resists	First :	18.82	Second :	20.48
Pivot price	18.63
Supports	First :	16.12	Second :	13.42
MAs	MA(5) :	17.9	MA(20) :	18.47
	MA(100) :	14.2	MA(250) :	13.52
MACD	MACD :	0	Signal :	0.4
%K %D	K(14,3) :	14.2	D(3) :	34.9
RSI	RSI(14): 40.9
52-week	High :	20.48	Low :	8.69

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IART ] has closed above bottom band by 2.6%. Bollinger Bands are 47.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	17.63 - 17.72	17.72 - 17.79
Low:	16.01 - 16.12	16.12 - 16.22
Close:	16.49 - 16.66	16.66 - 16.8

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Sat, 01 Aug 2026
integra lifesciences holdings corp Profit Warnings - RTTNews

Fri, 31 Jul 2026
Integra LifeSciences Holdings Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IART) 2026-07-31 - Seeking Alpha

Fri, 31 Jul 2026
Vanguard Portfolio Management (IART) discloses 3.9M-share position in Integra - Stock Titan

Thu, 30 Jul 2026
Integra LifeSciences (IART) Stock Rebounds As Margin Repair Gains Credibility - simplywall.st

Thu, 30 Jul 2026
Why Integra LifeSciences (IART) Shares Are Sliding Today - Yahoo Finance

Wed, 29 Jul 2026
Integra LifeSciences (NASDAQ: IART) swings from 2025 loss to Q2 2026 profit - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	78 (M)
Shares Float	59 (M)
Held by Insiders	14.2 (%)
Held by Institutions	100.1 (%)
Shares Short	6,210 (K)
Shares Short P.Month	7,220 (K)

EPS	-6.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.39
Profit Margin	-30.2 %
Operating Margin	10.4 %
Return on Assets (ttm)	2.5 %
Return on Equity (ttm)	-38.7 %
Qtrly Rev. Growth	2.4 %
Gross Profit (p.s.)	11.98
Sales Per Share	21.07
EBITDA (p.s.)	3.96
Qtrly Earnings Growth	0 %
Operating Cash Flow	71 (M)
Levered Free Cash Flow	69 (M)

PE Ratio	-2.58
PEG Ratio	0.6
Price to Book value	1.24
Price to Sales	0.78
Price to Cash Flow	18.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.